Y-biologics Inc.

Yonsei University

Korea Research Institute of Bioscience and Biotechnology

A&rt Co., Ltd.

Intocell, Inc.

Antibody and Receptor Therapeutics Co., Ltd.

Jae Eun Park

Young Woo Park

Bum-chan Park

Seok Ho Yoo

Young-Gyu Cho

Jung Chae Lim

Si Hyung Lee

Youngja Song

Hyun Mi Lee

Hye Nan Kim

Gi Sun Baek

Yeung Chul Kim

Sunha Yoon

Jisu Lee

Sang Pil Lee

Yunseon Choi

Ji-Young Shin

Bum-Chan Park

Dong Hee Lee

Yong Ho Lee

Soo Young Kim

Sung Ho Woo

Hyang Sook Lee

Sunyoung Kim

Jaeho Lee

Taekyo Park

Jongun Cho

Doohwan Jung

Myeoung Hee Jang

Suho Park

Beomseok Seo

Sangkwang Lee

Donghoon Seo

Ji Su Lee

Sanghyeon Yun

Okku Park

Ki Won Jo

Hyun Ju Lee

Sena Kim

Minah Seol

Joong Kyu Kim

Myeong Hee Jang

Chan Woong Park

Hye-Nan Kim

Hyun Kyung Lee

Soon Sil Hyun

Sun Jeong Jo

Bum Chan Park

Yosup Rew

Jina Song

Jihyeon Ha

Eun-Young Shim

Jin Chui Youn

Soo A Choi

Dong Jung Lee

Yunjung Ko

Bong-soo Cha

Yeung-Chul Kim

Eunjin Lee

Minju Lee

Gisun Baek

Jin Chul Youn

The present disclosure relates to antibody-drug conjugates (ADCs) wherein one or more active agents are conjugated to an anti-B7-H3 antibody through a linker. The linker may comprise a unit that covalently links active agents to the antibody. The disclosure further relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind B7-H3, as well as methods of making and using these anti-B7-H3 antibodies and antigen-binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications.

Antibody-drug conjugates comprising anti-B7-H3 antibodies

A monoclonal antibody or an antigen-binding fragment thereof according to an embodiment of the present invention can bind to lymphocyte-activation gene 3 (LAG-3) including a heavy chain variable region and a light chain variable region and inhibit the activity thereof. Thus it is expected to be useful for the development of immunotherapeutic agents for various disorders that are associated with LAG-3.

Monoclonal antibody specifically binding to LAG-3 and use thereof

The present invention relates to an antibody against delta-like 1 homolog () (DLK1) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector comprising the nucleic acid, a cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, an antibody drug conjugate (ADC) comprising the same, a pharmaceutical composition for treating cancer, a composition for diagnosing cancer, and a chimeric antigen receptor (CAR) and a T-cell engager comprising the same.

Antibody against human DLK1 and use thereof

Disclosed are an antibody to human programmed cell death 1 (PD-1) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector including the nucleic acid, an isolated cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, and a composition for preventing or treating cancer containing the same. The novel antibody binding to PD-1 or an antigen-binding fragment thereof can bind to PD-1 and inhibit the activity of PD-1, thus being useful for the development of immunotherapeutic agents for various diseases associated with PD-1.

Antibody to programmed cell death 1 (PD-1) and use thereof

Disclosed are an antibody to human programmed cell death-ligand 1 (PD-L1) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector including the nucleic acid, a cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, and a composition for preventing or treating cancer or infectious diseases containing the same.

Antibody to programmed death-ligand 1 (PD-L1) and use thereof

The present invention relates to compositions and methods for treating fatty liver, steatohepatitis, or liver cirrhosis as well as insulin resistance and aging by administration of a DLK1-Fc fusion protein constructed by conjugation of an extracellular domain of DLK1 or a fragment thereof with a human antibody Fc region. Also provided are health functional foods containing a DLK1-Fc fusion protein constructed by conjugation of an extracellular domain of DLK1 (delta-like 1 homolog) or a fragment thereof with a human antibody Fc region as an active ingredient.

Composition for preventing or treating fatty liver or insulin resistance syndrome including extracellular domain of delta-like 1 homolog

The present invention relates to a myostatin inhibitor comprising extracellular water-soluble domains of delta-like 1 homolog (DLK1) as active ingredients. More particularly, the present invention relates to a composition for inhibiting myostatin activity, comprising, as active ingredients, extracellular water-soluble domains of DLK1 or a deletion mutant of extracellular water-soluble domains of DLK1. The myostatin inhibitor of the present invention is bonded to the myostatin or activin receptor type IIB so as to inhibit the action mechanism of the myostatin, to thereby promote myogenesis and prevent differentiation into fat cells. Therefore, the myostatin inhibitor of the present invention may be used in preventing and treating diseases such as muscular dysplasia that requires differentiation to muscular cells, or metabolic diseases.

Myostatin inhibitor comprising extracellular water-soluble domains of DLK1 as active ingredient

The present invention relates to a drug conjugate comprising a cytotoxic drug conjugated to a c-Met specific human antibody. More specifically, the present invention relates to: a drug conjugate comprising a cytotoxic drug conjugated to a c-Met specific human antibody; a pharmaceutical composition for cancer treatment comprising the drug conjugate; and a cancer treatment method comprising a step in which the drug conjugate or pharmaceutical composition is administered to an individual.

Drug conjugate comprising drug linked to human c-Met antibody, and use therefor

Growing community of inventors

Daejeon, South Korea

Jae Eun Park